<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784275</url>
  </required_header>
  <id_info>
    <org_study_id>NMP-CYZ-P2-001</org_study_id>
    <nct_id>NCT02784275</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovMetaPharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovMetaPharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, placebo-controlled, parallel-group comparison study to
      evaluate the efficacy and safety of Cyclo-Z for the treatment of subjects with obese type 2
      diabetes.

      The study will consist of 3 phases:

        -  Screening phase (2 weeks)

        -  Treatment phase (12 weeks)

        -  Follow-up phase (2 weeks)

      Following a 2-week screening period, subjects who meet all inclusion and exclusion criteria
      will be randomly assigned into one of the following treatment arms:

        -  Dose A: Cyclo-Z containing 23 mg zinc plus 3 mg CHP - 16 subjects

        -  Dose B: Cyclo-Z containing 23 mg zinc plus 9 mg CHP - 16 subjects

        -  Dose C: Cyclo-Z containing 23 mg zinc plus 15 mg CHP - 16 subjects

        -  Dose D: Placebo - 16 subjects

      The assigned dose will be orally administered to subjects once a day before bedtime for 12
      consecutive weeks. After the randomization at Week 0 (Visit 2), subjects will visit their
      respective trial sites at Weeks 2, 4, 6, 8, 10, 12, and 14 (Visits 3, 4, 5, 6, 7, 8, and 9).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 9, 2016</start_date>
  <completion_date type="Actual">May 17, 2017</completion_date>
  <primary_completion_date type="Actual">May 3, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c Level From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in HbA1c from Day 1 to Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of Body Weight From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in body weight from Day 1 to Week 12</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of Fasting Plasma Glucose Level From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in fasting plasma glucose from Day 1 to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving HbA1c Goal of &lt;7.0%</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of subjects who achieved HbA1c of &lt;7% at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving HbA1c Goal of &lt;6.5%</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent of subjects who achieved HbA1c of &lt;6% at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in waist circumference from Day 1 to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Postprandial (2 Hours After Dinner) Blood Glucose Level From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in postprandial (2 hours after dinner) blood glucose levels from Day 1 to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Oral Glucose Tolerance Test From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change in oral glucose tolerance test results from Day 1 to Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Individual 19 domains were calculated as a weighted score (WS) for each domain. Average weighted impact score = summing of WS for each domain/19 domains. Total range possible is -9 to 3, and higher number means improvement in quality of life.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Diabetes Mellitus Type 2 in Obese</condition>
  <arm_group>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclo-Z</intervention_name>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_label>Dose B</arm_group_label>
    <arm_group_label>Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Dose D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged 18 or older.

          2. Subjects diagnosed with type 2 diabetes mellitus according to the American Diabetes
             Association (ADA) criteria.

          3. Subjects treated with stable doses of insulin and/or other hypoglycemic agent(s) for
             type 2 diabetes mellitus for at least 2 months prior to randomization.

          4. Subjects whose fasting blood glucose levels are reasonably stable for at least 2
             months prior to randomization and during the 2-week screening period.

          5. Subjects who have Hemoglobin A1c levels of 7.5 to 10.0 % at Screening.

          6. Subjects whose BMI is 30 or above.

          7. Subjects who can give written informed consent.

        Exclusion Criteria:

          1. Subjects who have any DM-related end-organ damages.

          2. Subjects who have a history of diabetic ketoacidosis or hyperosmolar non-ketotic coma.

          3. Subjects who have any disease likely to limit life span and/or increase risks of
             interventions such as:

               -  Carotid B-mode ultrasound test results indicating clinically significant stenosis
                  in the common carotid arteries requiring intervention by angioplasty or
                  resection.

               -  Cancer treatment in the past 5 years, with the exception of cancers which have
                  been cured, and carry a good prognosis.

               -  Infectious disease: HIV positivity, active tuberculosis, or pneumonia.

          4. Subjects who have any of the following conditions related to cardiovascular disease:

               -  Hospitalization for the treatment of heart disease in the past 12 months.

               -  New York Heart Association Functional Class &gt; 2.

               -  Left Bundle branch block on ECG at Screening.

               -  Third degree atrioventricular block on ECG at Screening.

               -  Uncontrolled hypertension with average systolic blood pressure of &gt; 160 mmHg or
                  diastolic blood pressure &gt; 95 mmHg at Screening and Baseline.

               -  Pulse rate &gt; 95 beats per minute at Screening and Baseline.

               -  Stroke or transient ischemic attack in the past 12 months.

          5. Subjects who have any of the following conditions related to gastrointestinal disease:

               -  Chronic hepatitis or cirrhosis.

               -  Episode of alcoholic hepatitis or alcoholic pancreatitis in the past 2 months.

               -  Inflammatory bowel disease requiring treatment in the past 12 months.

               -  Significant abdominal surgery (e.g., gastrectomy, gastric bypass) in the past 2
                  months.

          6. Subjects who have serum creatinine &gt; 1.5 mg/dL for male or &gt; 1.4 mg/dL for female.

          7. Subjects who have chronic obstructive airway disease or asthma requiring daily therapy
             or home use oxygen.

          8. Subjects who have hematocrit &lt; 36.0% for male or &lt; 33.0% for female.

          9. Subjects who have any of the following conditions or behaviors likely to affect the
             conduct of the study:

               -  Weight loss of &gt; 10% in the past 6 months.

               -  Unable to walk without assisted device.

               -  Major psychiatric disorder which would impede conduct of the research.

               -  Excessive alcohol intake (i.e., more than 2 drinks/day).

         10. Subjects who take any of the following medications:

               -  Psychoactive agents such as monoamine oxidase inhibitors and antidepressants
                  (e.g., lithium, Prozac, Zoloft, Serzone, Paxil, Effexor).

               -  Any other medications that may pose harm to the subject.

         11. Female subjects who have a positive serum pregnancy test at Screening, plan a
             pregnancy during study period, or are breast feeding.

         12. Female subjects who don't meet any of the following criteria:

               -  Surgically sterile (i.e., have had bilateral tubal ligation, hysterectomy, or
                  bilateral oophorectomy) at least 6 months before randomization.

               -  Post-menopausal for at least 12 months prior to Screening.

               -  If sexually active, they should use oral contraceptives, double barrier
                  contraception (e.g., condom with spermicide), intrauterine device, or other
                  methods approved by the Sponsor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Lee</last_name>
    <role>Study Director</role>
    <affiliation>KCRN Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 24, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <results_first_submitted>February 21, 2018</results_first_submitted>
  <results_first_submitted_qc>June 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 12, 2018</results_first_posted>
  <last_update_submitted>July 10, 2018</last_update_submitted>
  <last_update_submitted_qc>July 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02784275/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 9, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/75/NCT02784275/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>3 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="P2">
          <title>9 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="P3">
          <title>15 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="B2">
          <title>9 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="B3">
          <title>15 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="17"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Age of the subjects at the time of study entry.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.9" spread="7.58"/>
                    <measurement group_id="B2" value="59.9" spread="9.89"/>
                    <measurement group_id="B3" value="55.2" spread="10.90"/>
                    <measurement group_id="B4" value="57.1" spread="5.53"/>
                    <measurement group_id="B5" value="57.3" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change of HbA1c Level From Baseline</title>
        <description>Change in HbA1c from Day 1 to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However only 54 subjects had Week 12 values (12, 15, 14, and 13 subjects, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change of HbA1c Level From Baseline</title>
          <description>Change in HbA1c from Day 1 to Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However only 54 subjects had Week 12 values (12, 15, 14, and 13 subjects, respectively).</population>
          <units>(%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.979"/>
                    <measurement group_id="O2" value="-0.17" spread="1.038"/>
                    <measurement group_id="O3" value="-0.43" spread="1.132"/>
                    <measurement group_id="O4" value="-0.04" spread="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change of Body Weight From Baseline</title>
        <description>Change in body weight from Day 1 to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values for weight (12, 15, 14, and 13, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Body Weight From Baseline</title>
          <description>Change in body weight from Day 1 to Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values for weight (12, 15, 14, and 13, respectively).</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.73" spread="1.524"/>
                    <measurement group_id="O2" value="0.61" spread="3.4"/>
                    <measurement group_id="O3" value="-0.92" spread="2.381"/>
                    <measurement group_id="O4" value="2.38" spread="5.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Fasting Plasma Glucose Level From Baseline</title>
        <description>Change in fasting plasma glucose from Day 1 to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values (12, 15, 14, and 13, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Fasting Plasma Glucose Level From Baseline</title>
          <description>Change in fasting plasma glucose from Day 1 to Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values (12, 15, 14, and 13, respectively).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.4" spread="59.20"/>
                    <measurement group_id="O2" value="25.4" spread="65.66"/>
                    <measurement group_id="O3" value="5.3" spread="49.24"/>
                    <measurement group_id="O4" value="-23.4" spread="95.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving HbA1c Goal of &lt;7.0%</title>
        <description>Percent of subjects who achieved HbA1c of &lt;7% at Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values (12, 15, 14, and 13 respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving HbA1c Goal of &lt;7.0%</title>
          <description>Percent of subjects who achieved HbA1c of &lt;7% at Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values (12, 15, 14, and 13 respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Achieving HbA1c Goal of &lt;6.5%</title>
        <description>Percent of subjects who achieved HbA1c of &lt;6% at Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values (12, 15, 14, and 13, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Achieving HbA1c Goal of &lt;6.5%</title>
          <description>Percent of subjects who achieved HbA1c of &lt;6% at Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 54 subjects had Week 12 values (12, 15, 14, and 13, respectively).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference From Baseline</title>
        <description>Change in waist circumference from Day 1 to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 53 subjects had Week 12 values (12, 14, 14, and 13 respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference From Baseline</title>
          <description>Change in waist circumference from Day 1 to Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 53 subjects had Week 12 values (12, 14, 14, and 13 respectively).</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.71" spread="6.881"/>
                    <measurement group_id="O2" value="-1.31" spread="4.099"/>
                    <measurement group_id="O3" value="-0.70" spread="8.812"/>
                    <measurement group_id="O4" value="-0.79" spread="5.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Postprandial (2 Hours After Dinner) Blood Glucose Level From Baseline</title>
        <description>Change in postprandial (2 hours after dinner) blood glucose levels from Day 1 to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 51 subjects had Week 12 postprandial glucose values (11, 14, 14, and 12, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Postprandial (2 Hours After Dinner) Blood Glucose Level From Baseline</title>
          <description>Change in postprandial (2 hours after dinner) blood glucose levels from Day 1 to Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 51 subjects had Week 12 postprandial glucose values (11, 14, 14, and 12, respectively).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.56" spread="40.210"/>
                    <measurement group_id="O2" value="8.78" spread="38.543"/>
                    <measurement group_id="O3" value="-5.25" spread="62.754"/>
                    <measurement group_id="O4" value="-13.95" spread="54.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Oral Glucose Tolerance Test From Baseline</title>
        <description>Change in oral glucose tolerance test results from Day 1 to Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 53 subjects had Week 12 oral glucose tolerance test results (12, 15, 14, and 12, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Oral Glucose Tolerance Test From Baseline</title>
          <description>Change in oral glucose tolerance test results from Day 1 to Week 12</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 53 subjects had Week 12 oral glucose tolerance test results (12, 15, 14, and 12, respectively).</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="51.16"/>
                    <measurement group_id="O2" value="28.4" spread="89.45"/>
                    <measurement group_id="O3" value="-19.6" spread="85.62"/>
                    <measurement group_id="O4" value="-33.6" spread="75.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline</title>
        <description>Individual 19 domains were calculated as a weighted score (WS) for each domain. Average weighted impact score = summing of WS for each domain/19 domains. Total range possible is -9 to 3, and higher number means improvement in quality of life.</description>
        <time_frame>12 weeks</time_frame>
        <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 51 subjects had Week 12 ADDQoL results (9, 15, 14, and 13, respectively).</population>
        <group_list>
          <group group_id="O1">
            <title>3 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O2">
            <title>9 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O3">
            <title>15 mg CHP Plus 23 mg Zinc</title>
            <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change of Score in Audit of Diabetes-Dependent Quality of Life Questionnaire From Baseline</title>
          <description>Individual 19 domains were calculated as a weighted score (WS) for each domain. Average weighted impact score = summing of WS for each domain/19 domains. Total range possible is -9 to 3, and higher number means improvement in quality of life.</description>
          <population>Efficacy Analysis Set (N=61) was used for the efficacy analysis. However, only 51 subjects had Week 12 ADDQoL results (9, 15, 14, and 13, respectively).</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="2.311"/>
                    <measurement group_id="O2" value="0.21" spread="2.171"/>
                    <measurement group_id="O3" value="0.35" spread="1.075"/>
                    <measurement group_id="O4" value="1.53" spread="2.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>3 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 3 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="E2">
          <title>9 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 9 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="E3">
          <title>15 mg CHP Plus 23 mg Zinc</title>
          <description>Cyclo-Z containing 23 mg zinc plus 15 mg CHP
Cyclo-Z</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="16"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood insulin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Blood zinc increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haemotocrit decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Lee</name_or_title>
      <organization>NovMetaPharma Co., Ltd</organization>
      <phone>+82 (0)2 538 1893</phone>
      <email>Peter@NovMeta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

